SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-027611
Filing Date
2024-02-08
Accepted
2024-02-08 08:15:02
Documents
20
Period of Report
2024-02-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d761271d8k.htm   iXBRL 8-K 36953
2 EX-1.1 d761271dex11.htm EX-1.1 180480
3 EX-4.1 d761271dex41.htm EX-4.1 57231
4 EX-5.1 d761271dex51.htm EX-5.1 11152
5 EX-99.1 d761271dex991.htm EX-99.1 8326
9 GRAPHIC g761271dsp001a.jpg GRAPHIC 4312
10 GRAPHIC g761271dsp001b.jpg GRAPHIC 2092
  Complete submission text file 0001193125-24-027611.txt   508603

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tnya-20240207.xsd EX-101.SCH 2882
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tnya-20240207_lab.xml EX-101.LAB 18736
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tnya-20240207_pre.xml EX-101.PRE 11728
21 EXTRACTED XBRL INSTANCE DOCUMENT d761271d8k_htm.xml XML 3789
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 24606946
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)